Molbrick
Antimicrobial Agents for Treating Drug-resistant Mycobacteria
Company Overview
Snapshot
Founded in January 2019 by Barak Akabayov, Molbrick operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel antimicrobial agents. In June 2019, Molbrick graduated from the Inno-Negev Technology Accelerator.
Business overview
Molbrick is a Health Tech & Life Sciences startup developing novel antimicrobial agents to combat drug-resistant mycobacteria. The company's core technology, developed in Dr. Barak Akabayov's lab at Ben-Gurion University, involves designing small-molecule target cellular compartments essential for DNA replication. Molbrick operates within the Pharmaceuticals sector, targeting the Life Sciences and Healthcare & Life Sciences markets with its drug discovery and development efforts.
Log in to access full profile ›Company Intelligence Q&A
- When was Molbrick founded?
- Molbrick was founded in January 2019.
- Who is the founder of Molbrick?
- Barak Akabayov is the founder of Molbrick.
- What is Molbrick's primary focus?
- Molbrick focuses on developing novel antimicrobial agents to treat drug-resistant mycobacteria.
- What is Molbrick's current funding stage?
- Molbrick is currently in the Pre-Funding stage, having not yet disclosed any funding rounds.
- Has Molbrick participated in any accelerator programs?
- Yes, Molbrick graduated from the Inno-Negev Technology Accelerator in June 2019.